Company Filing History:
Years Active: 2013
Title: S Frank Yan: Innovator in Kinase Inhibitors
Introduction
S Frank Yan is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of kinase inhibitors. With a total of 2 patents, his work focuses on innovative compounds that address various diseases associated with abnormal kinase activity.
Latest Patents
S Frank Yan's latest patents include groundbreaking inventions in the realm of kinase inhibitors. The first patent, titled "Compounds and compositions as kinase inhibitors," introduces a novel class of 2,7-naphthyridin derivatives. This invention provides pharmaceutical compositions comprising these compounds and outlines methods for treating or preventing diseases linked to deregulated kinase activity, specifically targeting kinases such as Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, and c-FMS.
The second patent, "Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors," presents a class of compounds of Formula (I). Similar to his first patent, this invention details pharmaceutical compositions and methods for treating or preventing diseases associated with abnormal kinase activity, focusing on kinases like Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-IR, AIk, and c-FMS.
Career Highlights
S Frank Yan is currently associated with Irm LLC, where he continues to innovate and develop new pharmaceutical solutions. His expertise in kinase inhibitors has positioned him as a key figure in the pharmaceutical industry.
Collaborations
S Frank Yan has collaborated with notable colleagues, including Qiang Ding and Yahua Liu, to advance research and development in his field.
Conclusion
S Frank Yan's contributions to the development of kinase inhibitors highlight his innovative spirit and dedication to addressing critical health challenges. His patents represent significant advancements in pharmaceutical science, paving the way for new treatment options.